Risks to the Healthcare Business from Pharmaceutical Industry Trends and Regulatory Changes
First written in FY2016. 16 of 18 entries say "Restated". Latest entry: FY2024-Q3.
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
47 other companies' latest entry also says "Restated".
- FY2024-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there has been no new occurrence or material change concerning healthcare business risks arising from trends in the pharmaceutical industry and laws and regulations. - FY2024-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there has been no new occurrence or material change concerning healthcare business risks arising from trends in the pharmaceutical industry and laws and regulations. - FY2024-Q1RestatedAnnual report
「There were no newly occurring business or other risks during the cumulative first quarter of the current consolidated fiscal year. There have also been no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company states that there has been no new occurrence or material change concerning healthcare business risks arising from trends in the pharmaceutical industry and laws and regulations. - FY2023-Q1RestatedAnnual report
「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company states that there has been no new occurrence or material change concerning healthcare business risks arising from trends in the pharmaceutical industry and laws and regulations. - FY2022RestatedAnnual report
「The healthcare business may be significantly affected by trends in the pharmaceutical industry. If the market contracts due to a decline in new drug development in Japan or other factors, or depending on developments such as amendments to laws and regulations, including the Pharmaceuticals and Medical Devices Act, these factors may affect the Group’s operating results.」
The company continues to identify risks to the healthcare business arising from a contraction in the pharmaceutical market and amendments to laws and regulations, including the Pharmaceuticals and Medical Devices Act. - FY2021RestatedAnnual report
「The healthcare business may be significantly affected by trends in the pharmaceutical industry. If the market contracts due to a decline in new drug development in Japan or other factors, or depending on developments such as amendments to laws and regulations, including the Pharmaceuticals and Medical Devices Act, these factors may affect the Group’s operating results.」
The company continues to identify risks to the healthcare business arising from a contraction in the pharmaceutical market and amendments to laws and regulations, including the Pharmaceuticals and Medical Devices Act. - FY2021-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there has been no new occurrence or material change concerning healthcare business risks arising from trends in the pharmaceutical industry and laws and regulations. - FY2021-Q1RestatedAnnual report
「No new business or other risks arose during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there has been no new occurrence or material change concerning healthcare business risks arising from trends in the pharmaceutical industry and laws and regulations. - FY2020-Q1RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there has been no new occurrence or material change concerning healthcare business risks arising from trends in the pharmaceutical industry and laws and regulations. - FY2019-Q4RestatedAnnual report
「No new business or other risks arose during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there has been no new occurrence or material change concerning healthcare business risks arising from trends in the pharmaceutical industry and laws and regulations. - FY2019-Q2RestatedAnnual report
「In addition, the impact of active data collection, as seen in government efforts to contain medical costs and the introduction of MID-NET (※4), and accompanying changes in pharmaceutical manufacturers’ management policies and development activities are expected to affect the medium- to long-term growth of the company’s CRO business, but the company continues to aim to improve profitability by responding to changes in the external environment and reducing personnel costs through operational efficiency measures, including the introduction of RPA (Robotic Process Automation).」
The company continues to identify growth risks for the CRO business arising from efforts to contain medical costs, the introduction of MID-NET and changes in pharmaceutical manufacturers’ policies, while using operational efficiency measures, including the introduction of RPA, as countermeasures. - FY2019-Q1RestatedAnnual report
「In addition, the impact of active data collection, as seen in government efforts to contain medical costs and the introduction of MID-NET (※4), and accompanying changes in pharmaceutical manufacturers’ management policies and development activities are expected to affect the medium- to long-term growth of the company’s CRO business, but the company aims to improve profitability by responding to changes in the external environment and reducing personnel costs through operational efficiency measures, including the introduction of RPA (Robotic Process Automation).」
The company continues to disclose growth risks for the CRO business arising from efforts to contain medical costs, the introduction of MID-NET and changes in pharmaceutical manufacturers’ policies and development activities, while identifying operational efficiency measures, including the introduction of RPA, as countermeasures. - FY2018-Q4WorsenedAnnual report
「In addition, the impact of active data collection, as seen in government efforts to contain medical costs and the introduction of MID-NET, and accompanying changes in pharmaceutical manufacturers’ management policies and development activities are expected to affect the medium- to long-term growth of the company’s CRO business, but」
It was specifically stated that efforts to contain medical costs, the introduction of MID-NET and changes in pharmaceutical manufacturers’ management policies and development activities would affect the medium- to long-term growth of the CRO business. - FY2018RestatedAnnual report
「The healthcare business may be significantly affected by trends in the pharmaceutical industry. If the market contracts due to a decline in new drug development in Japan or other factors, or depending on developments such as amendments to laws and regulations, including the Pharmaceuticals and Medical Devices Act, these factors may affect the Group’s operating results.」
The company continues to identify a contraction in the pharmaceutical market and amendments to regulations, including the Pharmaceuticals and Medical Devices Act, as risks to the healthcare business. - FY2018-Q2RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there has been no new occurrence or material change concerning healthcare business risks arising from trends in the pharmaceutical industry and laws and regulations. - FY2018-Q1RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there has been no new occurrence or material change concerning healthcare business risks arising from trends in the pharmaceutical industry and laws and regulations. - FY2017RestatedAnnual report
「If the market contracts due to a decline in new drug development in Japan or other factors, or depending on developments such as amendments to laws and regulations, including the Pharmaceuticals and Medical Devices Act, these factors may affect the Group’s operating results.」
The company continues to identify a contraction in the pharmaceutical market and amendments to regulations, including the Pharmaceuticals and Medical Devices Act, as external risks to the healthcare business. - FY2016First statedAnnual report
「The healthcare business may be significantly affected by trends in the pharmaceutical industry. If the market contracts due to a decline in new drug development in Japan or other factors, or depending on developments such as amendments to laws and regulations, including the Pharmaceutical Affairs Law, these factors may affect the Group’s operating results.」
A contraction in the market due to declining new drug development and amendments to regulations, including the Pharmaceutical Affairs Law, are identified as external risks.